Nervous system drug 22.5 billion market, local pharmaceutical companies cover the top ten!

Medical Network September 10 - Neurological diseases occur in the central nervous system, peripheral nervous system, plant nervous system to sense, movement, consciousness, plant nerve dysfunction as the main manifestation of the disease.
common neurological disorders include cerebrovascular diseases (mainly stroke), Parkinson's disease, Alzheimer's disease (Alzheimer's disease), epilepsy and pain.
According to PDB data, in 2019, the domestic sample hospital nervous system drug sales of 22.462 billion yuan, ranked 5th in the treatment field, accounting for 8.81% of total drug sales, up 3.1% YoY, less than the average increase of 11.7% of total drug sales of about 8 percentage points.
its share of sales also decreased year by year, from 10.14 percent in 2017 to 8.81 percent in 2019.
can be seen that the increase in nervous system drug use is weaker than the "big market".
sub-field: the proportion of cerebrovascular drugs decreased from the sub-field, the first cerebrovascular disease medication accounted for about 40% of nervous system drugs, the proportion decreased year by year;
Analgesics, dementia drugs, anti-epileptic drugs and anti-Parkinson's drugs are basically chemical drugs in four sub-areas, and the amount of cerebrovascular medicine in terms of the amount of drugs and the proportion of Chinese medicine is 2.6:1, indicating that Chinese medicine in the sub-field of cerebrovascular diseases have a certain share.
sample hospitals in 2017-2019, sales of drugs in various sub-sectors of nervous system drugs: Tyzosin accounted for nearly 10% of neurological drugs from the drug point of view, Dzosin injections, oxycodam injections, butyl benzene injections, Ida lafon injections ranked in the top four.
in the drug TOP20, chemical drugs have 16, Chinese medicine only 4, the products of local enterprises dominated.
total sales of top20 sample hospitals exceeded 13.285 billion yuan, accounting for 59.11% of the sales of neurological drugs, accounting for nearly 60%, with a high concentration.
yangzijiang pharmaceutical industry alone, the dzizoxin injection accounted for nearly 10% of the total nervous system drug sales, it can be seen that the effect of head products is obvious.
sample hospital 2019 nervous system drug top 20 sales enterprises: local enterprises far ahead of the enterprise, the author listed the 2019 sample hospital nervous system drug sales of more than 300 million yuan manufacturers 20.
top 20 sample hospital sales of 12.544 billion yuan, accounting for 55.85 percent of the sales of nervous system drugs, TOP10 accounted for about 40 percent.
head enterprises have a major strategic product support in the market, such as Yangzijiang's Zosin, the stone drug Enbipu's butyl benzene, Jilin four ring of cerebrosine carnosine, Qilu's monosalic acid tetamine nerve glycoside lipids and so on.
top 20 manufacturers, 16 are local enterprises and 4 are multinational pharmaceutical companies.
in the nervous system, whether it is the number of enterprises or sample hospital drug sales, local enterprises far exceed foreign joint ventures.
sample hospital 2019 neurological drug manufacturer Top 20 sales according to CPM data, in domestic nervous system drugs, from January 2019 to June 2020, NMPA approved a total of 54 enterprises 76 drug production approvals.
Among them, 16 production approvals of 13 manufacturers (including 1 production approval of IdaRahfeng sodium chloride injections), the total number of approvals reached 27 enterprises and 35 production approvals;
these drug patents expire, companies are emulateing them and eventually over-competitive.
class 1.1 new class 1.1 drug GV-971 for the treatment of Alzheimer's disease has been launched, indicating that local enterprises in the field of neurological drug use has become a role that can not be ignored.
addition, Nanjing Yuke's Zosin injection has also been approved, will divide the field's largest variety of "big cake."
In the field of imported neurological drugs, from January 2019 to June 2020, NMPA approved 23 pharmaceutical production approvals in 11 varieties, including Novartis' multiple sclerosis treatment drug fingomod capsules and Sinimod tablets, as well as 5 anti-epileptic drugs, 2 other neurological drugs, 1 dementia treatment drug and 1 cerebrovascular drug.
in the study of products: the layout of new targets of new drugs from the nervous system drug in the research product pipeline, globally, the future treatment trend of Alzheimer's disease tends to be beta-amyloid targeted removal of direct therapies, while Parkinson's disease tends to target the glands Dopamine-assisted treatment of aside A2A receptors, CGRP antagonists and NGF antagonists dominate the market for chronic pain, and COX-2 selective nonsteroidal anti-inflammatory drugs (NSAIDs) are growing rapidly in the acute pain market.
local companies are emerging in the development of new drugs for Alzheimer's and Parkinson's disease, most notable for the recently approved GV-971, as well as the phase III clinical octahydroazine (acetylcholinesterase and butylcholinesterase inhibitors), L-yellow pylaide (beta-amyloid inhibitors), AD-35 and finkrosterone (SV2A regulators) in stage II.
Parkinson's drugs are mainly imitations, with several companies copying UCC's Rodigotin (dopamine D2, D3 astigtors) and fentanyl, US WorldMeds' sacpentine (dopamine reuptake and monoamine oxidase B inhibitors, ion channel blockers).
addition, because of the high cost of innovative drug research and development, generic competition, so improved new drugs by more and more enterprises, long-acting preparations and other new dosage forms should be considered or layout in common diseases, chronic diseases.
for domestic pharmaceutical enterprises, in addition to imitation of some key varieties with market potential, but also in the new preparations to work hard to form differentiated competition.
at the same time, clinical demand-oriented, pay attention to new treatment targets and new drug research and development progress at home and abroad, and gradually lay out the development of new therapeutic target new drugs, in the upgrading of therapeutic drugs occupy a leading position.
.